Arrowhead concludes enrolment in Phase IIb mixed dyslipidemia trial

The company anticipates concluding the trial by the end of this year; topline results will be reported in the first half of next year. Arrowhead Pharmaceuticals has concluded the subject enrolment as planned in the Phase IIb clinical trial of ARO-ANG3 to treat mixed dyslipidemia patients. A total of 182 subjects were currently enrolled into the trial. The company anticipates concluding the trial by the end of this year while topline results will be reported in the first half of next year. ARO-ANG3 is an investigational RNA interference (RNAi) therapeutic. Named ARCHES-2 or AROANG3-2001, the placebo-controlled, double-blind trial will analyse the safety and efficacy of ARO-ANG3 to treat mixed dyslipidemia in adult patients. The study will also enrol up to nearly 20 additional subjects, who were being screened when the trial reached the planned full enrolment. All dose arms enrolled a minimum of 60 subjects, who were randomised into a 3:1 ratio to receive either a subcutaneous dose of ARO-ANG3 or placebo on day one and week 12. ARO-ANG3

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!